Resource Logo
NLM AIDSLINE

Effectiveness of paramomycin in cryptosporidiosis in AIDS.




 

Int Conf AIDS. 1993 Jun 6-11;9(1):381 (abstract no. PO-B10-1473). Unique

OBJECTIVE: To determine the clinical effectiveness of paramomycin Humatin) in HIV-related cryptosporidial diarrhea. METHODS: 78 HIV-positive pts (average CD4 = 71.7 x 10(6)/L) with cryptosporidiosis received treatment with paramomycin at 1500-2000 mg/day. RESULTS: At the initiation of therapy, diarrhea was mild (2-4 bowel movements/day) in 35%, moderate (5-9/day) in 35% and severe (> 10/day) in 30%. The stool was described as liquid in 77% of cases. Clinical responses to paramomycin were as follows: complete (35%), partial (45%), or none (20%). Microbiologic eradication was documented in 37% of evaluable pts. 1 pt had to discontinue drug because of an allergic reaction. Clinical relapses were noted in 58% of responding pts an average of 2.2 mos after the initiation of paramomycin. In 50% the drug had been tapered or discontinued at the time of relapse. 42% of pts have not suffered a relapse an average of 4.7 mos after the initiation of treatment. In 25%, the drug has been discontinued. Of pts with clinical relapse, 28 were retreated with paramomycin. A partial clinical response was noted in 50%. Sixty-seven percent of pts remain alive an average of 5.9 mos following the diagnosis of cryptosporidiosis, 33% died an average of 3.8 mos following their diagnosis and in 80% cryptosporidium contributed significantly to death. CONCLUSION: 80% of pts with cryptosporidiosis had a favourable clinical response to paramomycin. Relapses were common and on average within 2 mos of initiation of treatment. Significantly fewer pts responded to retreatment with Humatin following relapse.

*AIDS-Related Opportunistic Infections/DRUG THERAPY *Cryptosporidiosis/DRUG THERAPY *HIV Seropositivity/COMPLICATIONS *Paromomycin/THERAPEUTIC USE



 




Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.